NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) early breast cancer (EBC).

Dennis J. Slamon,Peter A. Fasching,Ravindranath Patel,Sunil Verma,Sara A. Hurvitz,Stephen Chia,John Crown,Miguel Martin,Carlos H. Barrios,Gonzalo Spera,Celine Lopez,Inès Hor,Diana Pelov,Gareth Hughes,Moditha Nawinne,Gabriel N. Hortobagyi

NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) early breast cancer (EBC).

2019

Dennis J. Slamon
Peter A. Fasching
Ravindranath Patel
Sunil Verma
Sara A. Hurvitz
Stephen Chia
John Crown
Miguel Martin
Carlos H. Barrios
Gonzalo Spera
Celine Lopez
Inès Hor
Diana Pelov
Gareth Hughes
Moditha Nawinne
Gabriel N. Hortobagyi

TPS597Background: RIBO is a selective inhibitor of CDK4/6 with demonstrated efficacy and is well tolerated when combined with ET in pre-/peri- and postmenopausal women with HR+, HER2– advanced brea...

Keywords:

Hormone receptor
Cancer research
Adjuvant
Endocrine system
Peri
Pathology
Breast cancer
Ribociclib
Medicine
Human Epidermal Growth Factor Receptor 2
endocrine therapy
postmenopausal women
Oncology
early breast cancer
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations